General Information of MET (ID: META00294)
Name Glutaric acid
Synonyms   Click to Show/Hide Synonyms of This Metabolite
1,3-Propanedicarboxylate; 1,3-Propanedicarboxylic acid; 1,5-Pentanedioate; 1,5-Pentanedioic acid; Glutarate; Glutarsaeure; Pentandioate; Pentandioic acid; Pentanedioate; Pentanedioic acid
Source Endogenous;Escherichia Coli Metabolite;Food;Drug;Toxins/Pollutant;Cosmetic;TCM Ingredients;Microbial
Structure Type   Dicarboxylic acids and derivatives  (Click to Show/Hide the Complete Structure Type Hierarchy)
Organic acids and derivatives
Carboxylic acids and derivatives
Dicarboxylic acids and derivatives
PubChem CID
743
HMDB ID
HMDB0000661
Formula
C5H8O4
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=743"></iframe>
3D MOL 2D MOL
  Click to Show/Hide the Molecular/Functional Data (External Links/Property/Function) of This Metabolite
KEGG ID
C00489
DrugBank ID
DB03553
ChEBI ID
17859
FooDB ID
FDB001477
ChemSpider ID
723
METLIN ID
3254
Physicochemical Properties Molecular Weight 132.11 Topological Polar Surface Area 74.6
XlogP -0.3 Complexity 104
Heavy Atom Count 9 Rotatable Bond Count 4
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 4
Function
Glutaric acid is a simple five-carbon linear dicarboxylic acid. Glutaric acid is naturally produced in the body during the metabolism of some amino acids, including lysine and tryptophan. Glutaric acid may cause irritation to the skin and eyes. When present in sufficiently high levels, glutaric acid can act as an acidogen and a metabotoxin. An acidogen is an acidic compound that induces acidosis, which has multiple adverse effects on many organ systems. A metabotoxin is an endogenously produced metabolite that causes adverse health effects at chronically high levels. Chronically high levels of glutaric acid are associated with at least three inborn errors of metabolism, including glutaric aciduria type I, malonyl-CoA decarboxylase deficiency, and glutaric aciduria type III. Glutaric aciduria type I (glutaric acidemia type I, glutaryl-CoA dehydrogenase deficiency, GA1, or GAT1) is an inherited disorder in which the body is unable to completely break down the amino acids lysine, hydroxylysine, and tryptophan due to a deficiency of mitochondrial glutaryl-CoA dehydrogenase (EC 1.3.99.7, GCDH). Excessive levels of their intermediate breakdown products (e.g. glutaric acid, glutaryl-CoA, 3-hydroxyglutaric acid, glutaconic acid) can accumulate and cause damage to the brain (and also other organs). Babies with glutaric acidemia type I are often born with unusually large heads (macrocephaly). Macrocephaly is amongst the earliest signs of GA1. GA1 also causes secondary carnitine deficiency because glutaric acid, like other organic acids, is detoxified by carnitine. Abnormally high levels of organic acids in the blood (organic acidemia), urine (organic aciduria), the brain, and other tissues lead to general metabolic acidosis. Acidosis typically occurs when arterial pH falls below 7.35. In infants with acidosis, the initial symptoms include poor feeding, vomiting, loss of appetite, weak muscle tone (hypotonia), and lack of energy (lethargy). These can progress to heart, liver, and kidney abnormalities, seizures, coma, and possibly death. These are also the characteristic symptoms of untreated glutaric aciduria. Many affected children with organic acidemias experience intellectual disability or delayed development. In adults, acidosis or acidemia is characterized by headaches, confusion, feeling tired, tremors, sleepiness, and seizures. Treatment of glutaric aciduria is mainly based on the restriction of lysine intake, supplementation of carnitine, and an intensification of therapy during intercurrent illnesses. The major principle of dietary treatment is to reduce the production of glutaric acid and 3-hydroxyglutaric acid by restriction of natural protein, in general, and of lysine, in particular. Glutaric acid has also been found in Escherichia.
Regulatory Network
Full List of Protein(s) Regulating This Metabolite
      Divalent anion:Na symporter (DASS)
            Solute carrier family 13 member 2 (SLC13A2) Click to Show/Hide the Full List of Regulating Pair(s):   4 Pair(s)
               Detailed Information Protein   Info click to show the details of this protein
               Regulating Pair (1) Experim Info click to show the details of experiment for validating this pair [1]
                      Introduced Variation Mutation (M539C) of SLC13A2
                      Induced Change Glutaric acid concentration: decrease
                      Summary Introduced Variation         Induced Change 
                      Disease Status Healthy individual
                      Details It is reported that mutation (M539C) of SLC13A2 leads to the decrease of glutaric acid levels compared with control group.
               Regulating Pair (2) Experim Info click to show the details of experiment for validating this pair [1]
                      Introduced Variation Mutation (N525C) of SLC13A2
                      Induced Change Glutaric acid concentration: decrease
                      Summary Introduced Variation         Induced Change 
                      Disease Status Healthy individual
                      Details It is reported that mutation (N525C) of SLC13A2 leads to the decrease of glutaric acid levels compared with control group.
               Regulating Pair (3) Experim Info click to show the details of experiment for validating this pair [1]
                      Introduced Variation Mutation (T86C) of SLC13A2
                      Induced Change Glutaric acid concentration: decrease
                      Summary Introduced Variation         Induced Change 
                      Disease Status Healthy individual
                      Details It is reported that mutation (T86C) of SLC13A2 leads to the decrease of glutaric acid levels compared with control group.
               Regulating Pair (4) Experim Info click to show the details of experiment for validating this pair [1]
                      Introduced Variation Mutation (Y228C) of SLC13A2
                      Induced Change Glutaric acid concentration: decrease
                      Summary Introduced Variation         Induced Change 
                      Disease Status Healthy individual
                      Details It is reported that mutation (Y228C) of SLC13A2 leads to the decrease of glutaric acid levels compared with control group.
      Interleukin (IL)
            Interleukin-10 (IL10) Click to Show/Hide the Full List of Regulating Pair(s):   1 Pair(s)
               Detailed Information Protein   Info click to show the details of this protein
               Regulating Pair Experim Info click to show the details of experiment for validating this pair [2]
                      Introduced Variation Knockout of IL10
                      Induced Change Glutaric acid concentration: decrease
                      Summary Introduced Variation         Induced Change 
                      Disease Status Crohn disease [ICD-11: DD70]
                      Details It is reported that knockout of IL10 leads to the decrease of glutaric acid levels compared with control group.
      Lyases (EC 4)
            Selenocysteine lyase (SCLY) Click to Show/Hide the Full List of Regulating Pair(s):   1 Pair(s)
               Detailed Information Protein   Info click to show the details of this protein
               Regulating Pair Experim Info click to show the details of experiment for validating this pair [3]
                      Introduced Variation Knockout of Scly
                      Induced Change Glutaric acid concentration: increase
                      Summary Introduced Variation         Induced Change 
                      Disease Status Healthy individual
                      Details It is reported that knockout of Scly leads to the increase of glutaric acid levels compared with control group.
      Transcription factor (TF)
            R2R3-MYB (AN2) Click to Show/Hide the Full List of Regulating Pair(s):   1 Pair(s)
               Detailed Information Protein   Info click to show the details of this protein
               Regulating Pair Experim Info click to show the details of experiment for validating this pair [4]
                      Introduced Variation Overexpression of AN2
                      Induced Change Glutaric acid concentration: decrease (FC = 0.34)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Healthy individual
                      Details It is reported that overexpression of AN2 leads to the decrease of glutaric acid levels compared with control group.
      Transferases (EC 2)
            Succinate-hydroxymethylglutarate CoA-transferase (SUGCT) Click to Show/Hide the Full List of Regulating Pair(s):   1 Pair(s)
               Detailed Information Protein   Info click to show the details of this protein
               Regulating Pair Experim Info click to show the details of experiment for validating this pair [5]
                      Introduced Variation Knockout of Sugct
                      Induced Change Glutaric acid concentration: increase
                      Summary Introduced Variation         Induced Change 
                      Disease Status Diabetes mellitus [ICD-11: 5A14]
                      Details It is reported that knockout of Sugct leads to the increase of glutaric acid levels compared with control group.
References
1 Mapping Functionally Important Residues in the Na +/Dicarboxylate Cotransporter, NaDC1. Biochemistry. 2017 Aug 22;56(33):4432-4441.
2 Nontargeted urinary metabolite profiling of a mouse model of Crohn&#39;s disease. J Proteome Res. 2009 Apr;8(4):2045-57.
3 Combined Omics Reveals That Disruption of the Selenocysteine Lyase Gene Affects Amino Acid Pathways in Mice. Nutrients. 2019 Oct 26;11(11):2584.
4 Comprehensive Influences of Overexpression of a MYB Transcriptor Regulating Anthocyanin Biosynthesis on Transcriptome and Metabolome of Tobacco Leaves. Int J Mol Sci. 2019 Oct 16;20(20):5123.
5 Knockout of the non-essential gene SUGCT creates diet-linked, age-related microbiome disbalance with a diabetes-like metabolic syndrome phenotype. Cell Mol Life Sci. 2020 Sep;77(17):3423-3439.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.